Rajesh Kumar1, Grace Ledet2, Richard Graves2, Dibyadyuti Datta1, Shana Robinson2, Geetha P Bansal1, Tarun Mandal3, Nirbhay Kumar4. 1. Department of Tropical Medicine and Vector-Borne Infectious Diseases Research Center, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, 70112, USA. 2. Center for Nanomedicine & Drug Delivery, Xavier University of Louisiana, New Orleans, Louisiana, USA. 3. Center for Nanomedicine & Drug Delivery, Xavier University of Louisiana, New Orleans, Louisiana, USA. tmandal@xula.edu. 4. Department of Tropical Medicine and Vector-Borne Infectious Diseases Research Center, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, 70112, USA. nkumar@tulane.edu.
Abstract
PURPOSE: To evaluate functional immunogenicity of CHrPfs25. a malaria transmission blocking vaccine antigen, using nanoemulsion and porous polymeric PLGA nanoparticles. METHODS: CHrPfs25 was formulated with nanoemulsions (NE) and poly(D,L-lactide-co-glycolide) nanoparticles (PLGA-NP) and evaluated via IM route in mice. Transmission blocking efficacy of antibodies was evaluated by standard mosquito membrane feeding assay using purified IgG from immune sera. Physicochemical properties and stability of various formulations were evaluated by measuring poly-dispersity index, particle size and zeta potential. RESULTS: Mice immunized with CHrPfs25 using alum via IP and IM routes induced comparable immune responses. The highest antibody response was obtained with CHrPfs25 formulated in 4% NE as compared to 8% NE and PLGA-NP. No further increases were observed by combining NE with MPL-A and chitosan. One hundred percent transmission blocking activity was demonstrated at 400 μg/ml of IgG for alum groups (both routes IP and IM), 4% NE and NE-MPL-A. Purified IgG from various adjuvant groups at lower doses (100 μg/mL) still exhibited >90% transmission blocking activity, while 52-81% blocking was seen at 50 μg/mL. CONCLUSION: Results suggest that CHrPfs25 delivered in various adjuvants/nanoparticles elicited strong functional immunogenicity in pre-clinical studies in mice. We are now continuing these studies to develop effective vaccine formulations for further evaluation of immune correlates of relative immunogenicity of CHrPfs25 in various adjuvants and clinical trials.
PURPOSE: To evaluate functional immunogenicity of CHrPfs25. a malaria transmission blocking vaccine antigen, using nanoemulsion and porous polymeric PLGA nanoparticles. METHODS: CHrPfs25 was formulated with nanoemulsions (NE) and poly(D,L-lactide-co-glycolide) nanoparticles (PLGA-NP) and evaluated via IM route in mice. Transmission blocking efficacy of antibodies was evaluated by standard mosquito membrane feeding assay using purified IgG from immune sera. Physicochemical properties and stability of various formulations were evaluated by measuring poly-dispersity index, particle size and zeta potential. RESULTS:Mice immunized with CHrPfs25 using alum via IP and IM routes induced comparable immune responses. The highest antibody response was obtained with CHrPfs25 formulated in 4% NE as compared to 8% NE and PLGA-NP. No further increases were observed by combining NE with MPL-A and chitosan. One hundred percent transmission blocking activity was demonstrated at 400 μg/ml of IgG for alum groups (both routes IP and IM), 4% NE and NE-MPL-A. Purified IgG from various adjuvant groups at lower doses (100 μg/mL) still exhibited >90% transmission blocking activity, while 52-81% blocking was seen at 50 μg/mL. CONCLUSION: Results suggest that CHrPfs25 delivered in various adjuvants/nanoparticles elicited strong functional immunogenicity in pre-clinical studies in mice. We are now continuing these studies to develop effective vaccine formulations for further evaluation of immune correlates of relative immunogenicity of CHrPfs25 in various adjuvants and clinical trials.
Authors: D C Kaslow; I A Quakyi; C Syin; M G Raum; D B Keister; J E Coligan; T F McCutchan; L H Miller Journal: Nature Date: 1988-05-05 Impact factor: 49.962
Authors: Moustafa T Mabrouk; Wei-Chiao Huang; Bingbing Deng; Nasi Li-Purcell; Amal Seffouh; Joaquin Ortega; Gunes Ekin Atilla-Gokcumen; Carole A Long; Kazutoyo Miura; Jonathan F Lovell Journal: Int J Pharm Date: 2020-09-02 Impact factor: 5.875
Authors: Puthupparampil V Scaria; Beth Chen; Christopher G Rowe; David S Jones; Emma Barnafo; Elizabeth R Fischer; Charles Anderson; Nicholas J MacDonald; Lynn Lambert; Kelly M Rausch; David L Narum; Patrick E Duffy Journal: PLoS One Date: 2017-12-27 Impact factor: 3.240